⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
QNCX News
Quince Therapeutics, Inc. Common Stock
Quince Therapeutics Settles Approximately $16.4 Million of Debt
businesswire.com
QNCX
Form 8-K
sec.gov
QNCX
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
businesswire.com
QNCX
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
businesswire.com
QNCX
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
businesswire.com
QNCX
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
businesswire.com
QNCX
Quince Therapeutics to Participate at Investor Events in December 2025
businesswire.com
QNCX
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
businesswire.com
QNCX
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
businesswire.com
QNCX
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54 th Child Neurology Society Annual Meeting
businesswire.com
QNCX
QNCX